Lee's Pharmaceutical Holdings Ltd is an investment holding company principally engaged in the development, manufacturing, marketing and sales of pharmaceutical products. The Company operates its business through two segments. The Imported Products segment is engaged in the sale of imported products. Its imported products include Keyan injection, Fipril oral solution and others. The Proprietary Products segment is engaged in the manufacture and sale of self-developed products. Its R&D products include Resilicon Tablets, ADASUVE Inhalation Powder and others. The Company's medicines cover the fields of cardiovascular and infectious diseases, dermatology, oncology, gynecology and ophthalmology. The Company mainly operates its business in mainland China, Hong Kong and Taiwan.

Employees

1,094

Sector

Pharmaceuticals

Calendar

08-31 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
24/08/26	HK$1.135	-0.44%	141,000
21/08/26	HK$1.140	-1.30%	419,500
20/08/26	HK$1.155	-0.43%	308,500
19/08/26	HK$1.160	-0.43%	219,000
18/08/26	HK$1.165	+1.75%	150,000

Delayed Quote Hong Kong S.E.

More quotes

Net sales - Rate of surprise

Company calendar

Market Closed - Hong Kong S.E. 12:08:21 24/08/2026 +04			5-day change	1st Jan Change
1.135 ^HKD	-0.44%		-0.87%	-25.33%

07-31	Ashlins Obtains Exclusive Rights to Develop and Commercialize Certain Drug Products Incorporating Lee's Pharm's Interferon	CI
07-17	Lee?s Pharmaceutical Holdings Limited Enters into Exclusive License-Out and Supply Agreement with Ashlins Ocular Pharmaceuticals, Inc. for Interferon Alpha-2B Products Outside Greater China	CI

Market Cap	668M 85.25M 73.02M 68.32M 62.54M 117M 8.16B 119M 807M 315M 4.1B 320M 313M 13.55B	P/E 2024	8.98x	P/E 2025	9.74x
Enterprise Value	629M 80.19M 68.69M 64.27M 58.83M 110M 7.67B 112M 759M 296M 3.85B 301M 295M 12.75B	EV / Sales 2024	0.6x	EV / Sales 2025	0.6x
Free-Float	50.73%	Yield 2024	3.17%	Yield 2025	2.96%

07-31	Ashlins Obtains Exclusive Rights to Develop and Commercialize Certain Drug Products Incorporating Lee's Pharm's Interferon	CI
07-17	Lee?s Pharmaceutical Holdings Limited Enters into Exclusive License-Out and Supply Agreement with Ashlins Ocular Pharmaceuticals, Inc. for Interferon Alpha-2B Products Outside Greater China	CI
06-17	Lee's Pharmaceutical Launches HK$50 Million Share Buyback; Shares Jump 8%	MT
06-02	Lee's Pharmaceutical to Receive Gates Foundation Funding	MT
05-11	Lee's Pharmaceutical says Zhaoke Hefei to contribute RMB25 million to partnership fund	RE
03-30	Lee's Pharmaceutical Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-30	Lee's Pharmaceutical declares final dividend of HK2.3 cents per share	RE
03-30	Lee's Pharmaceutical Holdings Limited Recommends Final Dividend for the Year Ended December 31, 2025, Payable on June 15, 2026	CI
03-25	Lee's Pharmaceutical reports approval of Intrarosa by NMPA	RE
01-28	Lee's Pharmaceutical Receives Regulatory Nod to Move Production of Drug Within U.S.	MT
01-27	Lee's Pharmaceutical receives FDA approval of supplemental new drug application for Adasuve	RE
01-27	Lee's Pharmaceutical Holdings Limited Announces U.S. Food and Drug Administration Approval of Supplemental New Drug Application for ADASUVE	CI
01-23	Solasia Pharma Signs New Partner to Market and Manufacture Sancuso in China	MT

18/05/22	Sorrento Therapeutics' License Partner, Lee's Pharm, Announces Full Enrollment of 498 Patients in a Phase III Trial of Socazolimab (Anti-PD-L1 Antibody) for First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)	AQ
31/12/21	Listing on Guidance for Family Choice Pharmacy of Lee's Pharm signature products, Ferplex and Yallaferon	AQ
01/11/21	Sorrento’s License Partner, Lee’s Pharmaceutical Announces NDA Filing Acceptance by NMPA for Anti-PD-L1 Antibody Socazolimab for Treatment of Recurrent or Metastatic Cervical Cancer	AQ
14/05/21	Lee Pharmaceutical : Notice of Board Meeting	PU
29/04/21	Lee Pharmaceutical : (1) Establishment of Management Committee; (2) Resignation of Chief Executive Officer and Re-designation of Director; and (3) Change of Authorised Representative	PU

Lee's Pharmaceutical Holdings Limited Stock

Stocks

950

KYG5438W1116

Pharmaceuticals

Valuation: Lee's Pharmaceutical Holdings Limited

Chart: Lee's Pharmaceutical Holdings Limited

Latest news : Lee's Pharmaceutical Holdings Limited

Press Releases: Lee's Pharmaceutical Holdings Limited

Quotes and Performance

Course Extremes

Managers and Directors: Lee's Pharmaceutical Holdings Limited

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Net sales - Rate of surprise

1 day	-0.44%
1 week	-0.87%
Current month	+6.07%
1 month	-2.16%
3 months	+7.08%
6 months	-23.83%
Current year	-25.33%

1 week	1.12	1.18
1 month	1.04	1.22
Current year	0.99	1.69
1 year	0.99	2.7
3 years	0.99	2.7
5 years	0.99	4.17
10 years	0.99	14.7

Manager	Title	Age	Since
Wanee Leelalertsuphakun CEO	Chief Executive Officer	73	01/04/1997
Yiu Ming Chow DFI	Director of Finance/CFO	53	07/10/2014
Sze Ka Wong CTO	Chief Tech/Sci/R&D Officer	44	-

Director	Title	Age	Since
Siu Fong Lee CHM	Chairman	70	05/04/2010
Wanee Leelalertsuphakun BRD	Director/Board Member	73	01/12/2001
Xiao Yi Li BRD	Director/Board Member	63	01/09/2003

Date	Insider	Type	Main position	Quantity	% Market Cap.
15/10/25	Wanee Leelalertsuphakun	Other	Chief Executive Officer	588,000	0.0999%
15/10/25	Huby Technology Ltd.	Other	Company	588,000	0.0999%
15/10/25	Xiao Yi Li	Other	Founder	588,000	0.0999%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LEE'S PHARMACEUTICAL HOLDINGS LIMITED	-0.44%	-0.87%	-43.81%	-20.63%	85.62M
ELI LILLY AND COMPANY	-0.71%	+6.38%	+76.40%	+126.87%	1,119B
JOHNSON & JOHNSON	-0.07%	+3.80%	+50.73%	+64.25%	651B
ABBVIE INC.	-0.65%	+6.21%	+25.81%	+80.15%	468B
ROCHE HOLDING AG	-1.65%	+3.73%	+42.13%	+42.00%	374B
NOVARTIS AG	-1.08%	+2.19%	+24.56%	+40.33%	302B
ASTRAZENECA PLC	-1.55%	+4.29%	+1.55%	+12.15%	259B
AMGEN INC.	-0.58%	+5.81%	+49.57%	+70.71%	238B
NOVO NORDISK A/S	+0.29%	+3.56%	-17.56%	-53.11%	208B
GILEAD SCIENCES, INC.	-0.47%	+5.61%	+27.32%	+89.67%	181B
Average	-0.71%	+4.28%	+23.67%	+45.24%	379.99B
Weighted average by Cap.	-0.73%	+5.40%	+44.02%	+72.20%

	2024	2025
Net sales	1.4B 179M 153M 143M 131M 246M 17.09B 249M 1.69B 659M 8.58B 670M 656M 28.39B	1.44B 183M 157M 147M 134M 252M 17.52B 256M 1.73B 676M 8.8B 688M 673M 29.12B
Net income	93.1M 11.87M 10.17M 9.52M 8.71M 16.35M 1.14B 16.57M 112M 43.85M 571M 44.59M 43.62M 1.89B	91.94M 11.73M 10.05M 9.4M 8.6M 16.15M 1.12B 16.36M 111M 43.3M 564M 44.03M 43.07M 1.86B
Net Debt	10.45M 1.33M 1.14M 1.07M 978K 1.84M 128M 1.86M 12.63M 4.92M 64.08M 5.01M 4.9M 212M	-39.63M -5.05M -4.33M -4.05M -3.71M -6.96M -484M -7.05M -47.86M -18.67M -243M -18.98M -18.57M -804M